Executive functions disorders in children with dyslexia
Comparison in people · 2021
- What was studied
- 60 children with dyslexia; 60 healthy reference children
- Main finding
- Thirty treated patients received Cortexin and thirty encephabol; reading, attention and memory changes were reported.
Improvement rate · 73.3% Cortexin versus 60.0% Encephabol
Reported findings and study design
60 children with dyslexia, aged 8–11: Cortexin 30 versus Encephabol 30. Separate healthy comparison 60; treatment follow-up one month after completion.
Population or model 60 children with dyslexia; 60 healthy reference children
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Improvement rate | 73.3% Cortexin versus 60.0% Encephabol |
Healthy children supplied baseline context; they are not the drug-comparison control arm.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Healthy reference children are not an untreated dyslexia control; no established masking.
- Pediatric clinical findings do not establish enhancement or safety in healthy adults.
Source details
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Sources checked
Citation
Chutko LS, Surushkina SY, Yakovenko EA, I Anisimova T, Didur MD, Chekalova SA. Executive functions disorders in children with dyslexia Zh Nevrol Psikhiatr Im S S Korsakova 121(2):38-45. PMID 33728849
Study source ↗ · DOI 10.17116/jnevro202112102138 · Bibliography entry · Link to this summary